Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Mungara has over 25+ years of experience in the supply chain domain
Cipla completes transfer of Generics Business Undertaking
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Expands patient reach to remotest towns by furthering investment in GoApptiv
The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals
Commenced operations in flood-affected Himachal Pradesh
Subscribe To Our Newsletter & Stay Updated
